ArtemiC

PHASE II CONTROLLED CLINICAL STUDY

CLINICALLY VALIDATED

ArtemiC™ has been tested for safety and efficacy in a double-blind, placebo-controlled clinical trial of 50 patients diagnosed with COVID-19.

In the phase II clinical study, ArtemiC™ statistically improved the recovery of patients infected with COVID-19.

All patients had confirmed COVID-19 infection, were in stable, moderate condition in the hospital, and were between the ages of 40 and 75 years old.